Scott McMurry, PhD, is an associate in Mayer Brown's New York office and a member of the Intellectual Property practice. He focuses his practice on pharmaceutical patent litigation, particularly Hatch-Waxman litigation and related inter partes reviews, and on patent counseling, including global patent portfolio management and due diligence.
Scott regularly assists in a wide range of life science patent matters. He has worked on all phases of bet-the-company litigations up to trial, helping to protect flagship, multi-billion dollar drug products. Scott has experience preparing witnesses for testimony, including experts, inventors and company representatives. He regularly reviews intellectual property for licensing, merger and acquisition matters, and prepares freedom to operate and patentability opinions.
Scott is a registered US patent attorney. He has prosecuted global patent portfolios for research universities and drug discovery companies and has experience with patent oppositions in many countries.
Scott represents clients in adversarial proceedings at the US Patent and Trademark Office, including inter partes reviews. He has worked on teams that obtained the first-ever denials of IPR institution on patents covering prodrugs and pharmaceutical salts, which protect blockbuster drugs.
Prior to law school, Scott worked as a medicinal chemist in research and development at a drug discovery company.